Compare Crispr Therapeutics AG (CRSP) vs ProShares UltraPro Short QQQ ETF (SQQQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ProShares UltraPro Short QQQ ETF — how do they compare? Crispr Therapeutics AG trades at $50.61 (market cap $4.97B), while ProShares UltraPro Short QQQ ETF trades at $37.96. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, ProShares UltraPro Short QQQ ETF nearer its low. Which is the better fit depends on your goals.
| CRSP | SQQQ | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $76.78 | $97.60 |
52-Week Low | $44.34 | $36.31 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
SQQQ (ProShares UltraPro Short QQQ ETF) trades at $39.95, up 5.74% ($2.17) in the last session. The ETF shows a neutral technical signal overall with bullish moving averages and neutral oscillators. Recent news highlights SQQQ's role as a tactical hedging tool against Nasdaq 100 declines, though long-term performance erosion due to daily -3x leverage remains a concern. Short interest increased 19.4% in March 2026, reflecting bearish sentiment toward tech.
Outlook: SQQQ is a high-risk, short-term instrument for hedging QQQ exposure, not a long-term investment. Opportunities exist for tactical investors during tech selloffs, but risks include volatility decay, timing challenges, and structural erosion. Investors should understand the leveraged ETF's mechanics and use it cautiously within a diversified strategy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ProShares UltraPro Short QQQ ETF
SQQQ is a leveraged inverse ETF that seeks daily investment results, before fees and expenses, that correspond to three times the inverse (-3x) of the daily performance of the Nasdaq-100 Index. It is a tactical trading tool designed for sophisticated investors to profit from or hedge against declines in large-cap technology and growth stocks. Due to its daily reset and the effects of compounding, it is intended for short-term use and carries significant risk if held during periods of high market volatility.
Read more on SQQQ →
